Last reviewed · How we verify
NCT04650373
Durability of Weight Loss After Bariatric Surgery
trial testing Bariateric surgery in Obesity in 100 participants. Completed in 25 January 2020.
1 December 2019
Quick facts
| Lead sponsor | Al-Azhar University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 17 January 2014 |
| Primary completion | 1 December 2019 |
| Estimated completion | 25 January 2020 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Bariateric surgery
Conditions studied
- Obesity — all drugs for Obesity →
Sponsor
Al-Azhar University
Who can join
Adults 18 to 80, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The present study is a retrospective cohort study. Patients older than 18 years of age and underwent Roux-en-Y gastric bypass (RYGB) surgical treatment during the period from 2014 to 2019 and paired severely overweight controls who had no longer gone through bariatric surgery. Patients having BMI (Body Mass Index) much lower than 35 (calculated as the weight (kilograms) / length2 (meters)), a base line diagnosis taken into consideration a medical exclusion for surgical treatment died in one year of surgical operation and missed statistics at scientific information had been excluded from the study. The primary final results of the study was the weight-change percentage at follow-up in comparison with baseline one and the clinical events after surgery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04650373
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other Al-Azhar University trials
Trials by the same sponsor.
- NCT06489327 — Comparing Two Doses of Oral Melatonin as Premedication in Children Undergoing Surgery · NA · recruiting
- NCT07327918 — Effect of Epidural Needle Injection on Catheter Placement Success During Painless Labour · Phase 3 · not yet recruiting
- NCT07500194 — Quad Helix vs RME for Posterior Cross-bite in Egyptian Children · NA · not yet recruiting
- NCT07360756 — Ultrasonographic ONSD as a Predictor of PDPH in Spinal Anesthesia for Cesarean Delivery · not yet recruiting
- NCT07343570 — Comparison of Quadratus Lumborum and Combined Groin Nerve Blocks for Postoperative Analgesia After Open Inguinal Hernia · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04650373 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Al-Azhar University
- Last refreshed: 2 December 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04650373.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing